Quoin Pharmaceuticals Opens At-the-Market ADS Offering With 3% Sales Commission

What happened

Quoin Pharmaceuticals entered into an at-the-market sales agreement with Leerink Partners, allowing it to sell American Depositary Shares, or ADSs, from time to time on Nasdaq or another trading market. Leerink receives 3% of gross proceeds from sales it handles, and Quoin can suspend or end the offering at any time with notice.

Confirmed

Global impact / market context

The agreement gives Quoin a way to raise cash by selling shares over time rather than through one fixed sale. The 3% commission reduces the proceeds from sales handled by Leerink, while issuing additional ADSs can dilute existing shareholders’ ownership.

Analyst inference

The article reports an available fundraising route, not that Quoin has already sold ADSs or raised cash. The financial effect therefore depends on whether the company uses the agreement, how many shares it sells, and the gross proceeds generated.

Analyst inference

What to watch

1. Watch for company disclosures confirming ADS sales, their timing, and gross proceeds; those details would show whether this agreement has actually brought cash into Quoin. Analyst inference
2. Track any notice that Quoin suspends or terminates the offering, since the agreement allows either action at the company’s discretion. Confirmed
3. Compare future fundraising updates with the 3% commission and any disclosed share issuance to assess cash raised after fees and potential ownership dilution, meaning existing investors own a smaller share of the company. Analyst inference

Evidence

• Original source link unavailable